Press Releases | Clarus Therapeutics, Inc

Skip to main navigation

Investor Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly & Annual Reports
IR Resources
- Email Alerts
- Contact IR

Press Releases

Year

Oct 18, 2022

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

Sep 05, 2022

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Aug 18, 2022

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

Jul 28, 2022

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

Jun 09, 2022

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

May 18, 2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

May 16, 2022

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

May 12, 2022

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

May 10, 2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

May 09, 2022

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

2022 Copyright

Search Investor Relations